WO2026118186 - METHOD FOR PRODUCING ANTI-CD38 ANTIBODY

National phase entry is expected:
Publication Number WO/2026/118186
Publication Date 11.06.2026
International Application No. PCT/CN2025/074774
International Filing Date 24.01.2025
Title **
[English] METHOD FOR PRODUCING ANTI-CD38 ANTIBODY
[French] PROCÉDÉ DE PRODUCTION D'UN ANTICORPS ANTI-CD38
[Chinese] 用于生产抗CD38抗体的方法
Applicants **
QILU PHARMACEUTICAL CO., LTD.
Inventors
FU, Maohong
ZHANG, Jianjun
AN, Zhenming
SUN, Lixia
ZHENG, Huanlan
SHI, Qinghua
DONG, Bei
ZHU, Shibo
Priority Data
202411782739.2   05.12.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting1866
EPO Filing, Examination, Granting14225
Japan Filing, Examination, Granting2331
South Korea Filing, Examination, Granting2442
USA Filing, Examination, Granting4740
MasterCard Visa
Total: 25,604
Contact Us
Abstract[English] Provided in the present invention are a method for controlling the concentration of Mn ions during the preparation of an anti-CD38 antibody so as to improve the content of G1F and G0F oligosaccharide modifications of the antibody, and a method for formulating the antibody into a pharmaceutical product.[French] La présente invention concerne un procédé de contrôle de la concentration en ions Mn lors de la préparation d'un anticorps anti-CD38 afin d'améliorer la teneur en modifications oligosaccharidiques G1F et G0F de l'anticorps, ainsi qu'un procédé de formulation de l'anticorps en un produit pharmaceutique.[Chinese] 本发明提供了一种在抗CD38抗体制备期间控制Mn离子浓度从而改善抗体G1F、G0F低聚糖修饰含量的方法,以及将所述抗体配制为药物产品的方法。

Rejoining the server...